Showing 7541-7550 of 8194 results for "".
- Valeant Enters Fulfillment Agreements With Walgreenshttps://practicaldermatology.com/news/valeant-enters-fulfillment-agreements-with-walgreens/2458783/Valeant Pharmaceuticals International, Inc. entered into new fulfillment agreements with Walgreens and indicated that it intends to extend this distribution model to additional participating independent retail pharmacies. In conjunction with the fulfillment agreement, Valeant says it will reduce
- Valeant Offers Comment on Fake Twitter Accounthttps://practicaldermatology.com/news/valeant-offers-comment-on-fake-twitter-account/2458786/Valeant issued the following statement about a fake Twitter account created to impersonate Mike Pearson: We are aware that someone impersonating Mike Pearson has created an account on Twitter, and we have contacted Twitter to report the unauthorized use. Mike Pearson does not
- Safe, Inexpensive Chemical Found to Reverse Symptoms of Progeria in Human Cellshttps://practicaldermatology.com/news/safe-inexpensive-chemical-found-to-reverse-symptoms-of-progeria-in-human-cells/2458787/New work from the University of Maryland suggests that a common, inexpensive and safe chemical called methylene blue could be used to treat progeria—and possibly the symptoms of normal aging as well. A new study shows for the first time that small doses of methylene blue can almost complete
- ASDS Awards Inagural Research Grant Recipient of Fredric S. Brandt, MD, Innovations in Aesthetics Fellowshiphttps://practicaldermatology.com/news/asds-awards-inagural-research-grant-recipient-of-fredric-s-brandt-md-innovations-in-aesthetics-fellowship/2458790/Abigail Waldman, MD, of Chicago, has been chosen as the inaugural research grant recipient of the Fredric S. Brandt, MD, Innovations in Aesthetics Fellowship Fund. Dr. Waldman was awarded $41,500 for her research project entitled “Patient Motivations and Preferences Regarding the De
- AAD Issues Statement on Skin Cancer Screeninghttps://practicaldermatology.com/news/aad-issue-statement-on-skin-cancer-screening/2458789/Mark G. Lebwohl, MD, FAAD, President, American Academy of Dermatology issued the following statement on skin cancer screenings: “The American Academy of Dermatology believes that early detection is vital in the fight against skin cancer, the most common cancer in the United States.
- Cosmetic Surgery Forum Wraps Seventh Successful Yearhttps://practicaldermatology.com/news/cosmetic-surgery-forum-wraps-seventh-successful-year/2458791/Covering topics from the appropriate use of permanent fillers to the role of spirituality in practice, the seventh annual Cosmetic Surgery Forum (CSF) brought together experts from multiple specialties at the Aria in Las Vegas this month. The three-day program included guidance on practice manage
- Aqua Pharmaceuticals Acquires US Rights to Veltin Gel and Altabax Ointmenthttps://practicaldermatology.com/news/aqua-pharmaceuticals-acquires-us-rights-to-veltin-gel-and-altabax-ointment/2458795/Aqua Pharmaceuticals, LLC acquired the US rights to two dermatology products— Veltin (clindamycin phosphate and tretinoin) Gel 1.2%/0.025% and Altabax (retapamulin) Ointment 1%, after Almirall, parent company of Aqua, acquired the rights to the products from GlaxoSmithKline. Both Veltin and
- AAD Releases New App to Aid Patients with Chronic Hiveshttps://practicaldermatology.com/news/aad-releases-new-app-to-aid-patients-with-chronic-hives/2458798/The American Academy of Dermatology (AAD) released its Chronic Hives Patient App, which offers tools and resources for chronic hives management. The free mobile app, developed with a grant from Novartis Pharmaceuticals Corp., can help patients learn more about their condition, find a doctor, trac
- Novartis receives FDA regular approval for Tafinlar + Mekinist for Melanomahttps://practicaldermatology.com/news/novartis-receives-fda-regular-approval-for-tafinlar-mekinist-for-melanoma/2458804/The FDA granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) from Novartis for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. This is th
- Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Companyhttps://practicaldermatology.com/news/almirall-acquires-veltin-and-altabax-from-stiefel-a-gsk-company/2458802/Almirall has acquired the rights to Veltin® and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino® and an undisclosed cash payment.